BioStem Technologies, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting a year of strategic transition marked by revenue declines offset by strong gross margins and a significant acquisition. The regenerative medicine company, which focuses on perinatal tissue allograft products, generated net revenue of $10.1 million for the fourth quarter of 2025, representing a 55% decrease compared to the same period in 2024. For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024. The company attributed these declines primarily to reimbursement uncertainty and increased competitive pressure in the physician office and mobile settings for wound care products.
Despite the revenue challenges, BioStem maintained robust gross margins. Fourth quarter gross profit was $9.8 million, or 97% of net revenue, compared to $19.1 million or 84% of net revenue in Q4 2024. The company noted the increase in gross margin percentage reflected a product mix shift toward products that do not carry a licensing fee. For the full year 2025, gross profit was $44.4 million, or 94% of net revenue, compared to $55.9 million or 80% of net revenue for 2024. The company reported a GAAP net loss of ($11.3 million) or ($0.67) per share for the fourth quarter, compared to net income of $14.7 million or $0.89 per share in Q4 2024. Full year 2025 GAAP net loss was ($6.6 million), compared to net income of $31.0 million for 2024.
A key development for BioStem was the January 2026 acquisition of the BioTissue Holdings Inc. surgical and wound assets. This strategic move significantly expands the company's product portfolio and commercial footprint while diversifying its end markets into the hospital setting. The integration includes BioTissue's experienced national sales force of approximately 20 direct sales representatives and managers, plus more than 30 independent sales agents. Following the acquisition closing on January 21, 2026, BioStem's cash equivalents balance totaled approximately $16 million, down from $29.5 million as of December 31, 2025. The company's portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines, with more information available at https://biostemtechnologies.com.
Jason Matuszewski, CEO and Chairman of the Board of BioStem, stated the company delivered a solid finish to 2025 with fourth quarter revenue reflecting continued penetration of the physician office market. He emphasized that entering 2026, BioStem is a fundamentally stronger and more diversified regenerative medicine company following the BioTissue acquisition. The company believes it is well positioned to navigate the evolving reimbursement landscape with focused commercial channels serving both hospital and physician office settings and increased exposure to commercially insured patient populations.
Looking ahead to 2026, BioStem provided financial outlook commentary, anticipating first quarter revenue in the range of $5 million to $6 million. The company expects the hospital business to perform in line with historical levels of the acquired assets, adjusted for the January acquisition date, while the physician office business is expected to be down significantly from the prior quarter. For the second half of 2026, after completing integration activities, expanding its salesforce and executing its strategic plan, the company expects to drive sequential and year-over-year growth in the hospital business. As the physician office market begins to stabilize in the second half of 2026, BioStem sees an opportunity for sequential revenue growth improvement in that business.
The company also provided an update on its Nasdaq uplisting efforts, noting that KPMG LLP was appointed as its independent registered public accounting firm in October 2025. BioStem expects to have audited financial statements for 2024 and 2025 in the near future, a key prerequisite for pursuing a Nasdaq uplisting. The latest news and updates relating to the company are available in its newsroom at https://tinyurl.com/bsemnewsroom. For investors and industry observers, BioStem's 2025 results illustrate the challenges facing regenerative medicine companies in reimbursement-sensitive markets, while its strategic acquisition and integration plans demonstrate a pathway toward diversification and potential resilience in the evolving healthcare landscape.
